Madison-based biotechnology firm FluGen Inc. has raised a $5.6 million debt funding round to continue its development of a universal flu vaccine.
“We’re doing something no one’s ever done, to our knowledge,” Radspinner said. “What we did was to give about 100 volunteers, half of them received our vaccine, half received a placebo, and then a month later they were all given the flu.”
FluGen then measured whether the patient became ill or not, and the severity of symptoms. It expects the results of the first challenge study in the first quarter of 2019.
Read more at BizTimes.